Site Supervisor - Orlando

Sago, formerly Schlesinger Group, is the global research and data partner that connects human answers to business questions. Combining our legacy of impact, global reach, and innovative spirit, we enable our clients to solve business problems through extensive audience access and an adaptive range of qualitative and quantitative solutions. We help our clients understand what their customers want and demand - empowering them to make decisions with confidence. As a partner to our clients, their clients, and the industry, Sago seamlessly connects businesses to key insights.

Join our team at SAGO, where happiness thrives in the top 35%, our work culture ranks in the top 10%, and diversity shines in the top 15% compared to peers of our size. Discover more about us at https://www.comparably.com/companies/sago

Position Summary

The Site Supervisor provides day‑to‑day leadership and operational oversight for site staff supporting the PMTA study. This role holds primary accountability for site‑level protocol execution, regulatory compliance, investigational product control, and staff performance.

Key Responsabilities

• Provide direct supervision and day‑to‑day management of site staff supporting the PMTA study
• Work with Facility Director/Manager to assign, oversee, and balance staff responsibilities to ensure adequate coverage for subject visits and study activities
• Monitor staff performance and adherence to study protocols, SOPs, and regulatory requirements
• Maintain overall responsibility for site‑level compliance with the study protocol, applicable SOPs, and regulatory requirements
• Ensure informed consent is obtained and documented correctly for all subjects prior to any study‑related procedures
• Oversee the accuracy, completeness, and maintenance of all regulated study documentation and source records
• Oversee subject screening, enrollment, and retention activities to ensure consistent, compliant execution
• Work with Clinical Project Management team to support complex subject interactions, escalated concerns, or compliance‑related issues